Ethyl 8-(2,3,4-trimethoxyphenyl)-8-oxooctanoate, 97.0%, 1g

(S)-3-Isobutylmorpholine, 95.0%, 250mg

alpha,alpha,alpha',alpha'-Tetrabromo-p-xylene>98.0%(GC)25g

C-{1-[2-(4-Aminomethyl-piperidin-1-yl)-ethyl]-piperidin-4-yl}-methylamine, 1g

N-Methyl-3-aminopropyltrimethoxysilane(3-Trimethoxysilyl propylmethylamine), 95%, 25g

(S)-2,2,2-Trifluoro-1-phenylethylaminehydrochloride, 95.0%, 500mg

Methyl 3-amino-5-nitrothiophene-2-carboxylate, 95+%, 1g

Sulfato de quinidina dihidrato, mínimo 99 %, 10 g, envase de vidrio

(1R,2S)-2-((TERT-BUTOXYCARBONYL)AMINO)CYCLOHEXANE-1-CARBOXYLIC ACID, 95%, 1g

Ethyl 3,5-difluorobenzoylformate, 96.0%, 5g

(3-Bromopyridin-2-yl)methanol, 95.0%, 5g

(S)-2-(4-Chlorophenyl)-3-methylbutanoic acid, 95.0%, 5g

(4-CYCLOBUTYLPHENYL)METHANAMINE, 95.0%, 250mg